It has been estimated that chronic cough affects up to 10% of the US population, with one in five of them getting no benefit from current treatments such as opioids and corticosteroids.

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Chronic cough remains a persistent challenge for clinicians ... Duffy disclosed consultant relationships with Merck and with Bellus Health (now GSK). Irwin disclosed royalties as a codeveloper ...

Please provide your email address to receive an email when new articles are posted on . Camlipixant is a P2X3 antagonist. Studied patients had a baseline awake cough frequency of at least 25 ...

Trevi is also conducting the phase IIb CORAL study, which is evaluating the drug in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Data from this study is expected in the first ...

GSK expects to launch its RCC drug commercially in 2026. Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two complete response ...